Expression profile of early lung adenocarcinoma: Identification of MRP3 as a molecular marker for early progression

Journal of Pathology

Volumn 216, Issue 1, 2008, Pages 75-82

  Hanada, S ^a,c   Maeshima, A ^a,e   Matsuno, Y ^a,d   Ohta, T ^a   Ohki, M ^a   Yoshida, T ^a   Hayashi, Y ^b   Yoshizawa, Y ^c   Hirohashi, S ^a   Sakamoto, M ^a,b  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

Author keywords

Expression profile; Localized non mucinous BAC (LNMBAC); Lung adenocarcinoma; Microarray; MRP3

Indexed keywords

AQUAPORIN 3; CLAUDIN 4; MOLECULAR MARKER; MULTIDRUG RESISTANCE PROTEIN 3; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CELL MEMBRANE; CELL TYPE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL TYPE 2; MALE; PRIORITY JOURNAL; UPREGULATION;

ADENOCARCINOMA; AGED; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 50249099312     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2383     Document Type: Article

References (25)

1. Yamasaki M, Takeshima, Fujii S, Matsuura M, Tagawa K, Inai K. Correlation between morphological heterogeneity and genetic alteration within one tumor in adenocarcinomas of lung. Pathol Int 2000;50:891-896.
2. Chapman AD, Kerr KM. The association between atypical adenomatous hyperplasia and lung cancer. Br J Cancer 2000;83:632-636.
3. Kitamura H, Kameda Y, Takaaki I, Hayashi H. Atypical adenomatous hyperplasia of lung. Am J Clin Pathol 1999;111:610-622.
4. Niho S, Yokose Y, Suzuki K, Kodama T, Nishiwaki Y, Mukai K. Monoclonality of atypical adenomatous hyperplasia of lung. Am J Pathol 1999;154:249-254.
5. Nakahara R, Yokose T, Nagai K, Nishiwaki Y, Ochiai A. Atypical adenomatous hyperplasia of the lung: a clinicopathological study of 118 cases including cases with multiple atypical adenomatous hyperplasias. Thorax 2001;56:302-305.
6. Nomori H, Horio H, Naruke T, Suenuma K, Morinaga S, Noguchi M. A case of multiple atypical adenomatous hyperplasia of lung detected by computer tomography. Japan J Clin Oncol 2001;31:514-516.
7. Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada M, Hirohashi S, et al. Small adenocarcinoma of the lung. Cancer 1995;75:2844-2852.
8. Aoyagi Y, Yokose T, Minami Y, Ochiai A, Iijima T, Morishita Y, et al. Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma. Cancer Res 2001;61:7950-7954.
9. Kurasono Y, Ito T, Kameda Y, Nakamura N. Kitamura H. Expression of cyclin D1, retinoblastoma gene protein, and p16 MTS1 protein in atypical adenomatous hyperplasia and adenocarcinoma of lung. Virchows Arch 1998;432:207-215.
10. Maeshima A, Sakamoto M, Hirohashi S. Mixed mucinous-type and non-mucinous-type adenocarcinoma of the lung: immunohistochemical examination and K-ras gene mutation. Virchows Arch 2002;440:598-603.
11. Slebos R, Baas I, Clement M, Offerhaus J, Askin F, Hruban R, et al. p53 alterations in atypical alveolar hyperplasia of the human lung. Human Pathol 1998;29:801-808.
12. Bhattachrjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98:13790-13795.
13. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001;98:13784- 13789.
14. Tomida S, Koshikawa K, Yatabe Y, Harano T, Ogura N, Mitsudomi T, et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene 2004;23:5360-5370.
15. Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M, et al. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 2003;37:198-207.
16. Kool M, Liden M, Haas M, Schffer GL, Vree JM, Smith AJ, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 1999;96:6914-6919.
17. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003;8:411-424.
18. Fukuoka-Uesaka H, Saito Y, Maekawa K, Hasegawa R, Suzuki K, Yanagawa T, et al. Genetic variation of the ABC transporter gene ABCC3 in a Japanese population. Drug Metab Pharmacokinet 2007;22(2):129-135.
19. Belinsky MG, Dawson PA, Shchaveleva I, Bain LJ, Wang R, Ling V, et al. Analysis of the in vivo functions of Mrp3. Mol Pharmacol 2005;68(1):160-168.
20. Oguri T, Isobe T, Fujita K, Ishikawa N, Kohno N. Association between expression of the MRP3 gene and exposure to platinum drugs in lung cancer. Int J Cancer 2001;93:584-589.
21. Young LC, Campling BG, Cole SPC, Deeley RG, Gerlach JH. Multidrug resistance protein MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res. 2001;7:1798-1804.
22. Miller VA, Hirch FA, Johnson DH. Systemic therapy of advanced bronchiolar cell carcinoma: challenges and opportunities. J Clin Oncol. 2005;23(14):3288-3293.
23. Hadnagy A, Gaboury L, Beaulieu R, Balicki D. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 2006;312(19): 3701-3710.
24. Ho MM, Ng AV, Lam S, Hung JY. Side population on human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007;67(10):4827-4833.
25. Fehrenbach H. Alveolar epithelial type II cell: defender of the alveolus revisited. Respir Res 2001;2:33-46.